



Abstract and Case Policies and Procedures

(Updated May 2026)

The American College of Cardiology Foundation (hereinafter referred to as “ACC”) is accepting Abstract, Complex Clinical Case, CVT Abstract, and CVT Case submissions for the American College of Cardiology's 76th Annual Scientific Session & Expo Together With World Congress of Cardiology in Houston, TX, April 10 – 12, 2027 (“ACC.27-WCC”). The submission site will be open from Tuesday, Aug. 25, 2026, until **Tuesday, Oct. 6, 2026, at 1 p.m. ET.**

Please Note: All presentations must be **in-person** for ACC.27-WCC. We are not offering virtual or remote presentation capabilities for peer-reviewed research. If your submission is accepted, we hope you or a co-author can present in-person. If no one can present in-person, your accepted submission will be withdrawn from the program. However, it will still be published in *JACC* unless you withdraw it by Thursday, February 4, 2027.

Please read the following instructions carefully:

Section 1 details the submission types.

Section 2 contains important information about submitting your abstract and case.

Section 3 contains information for accepted abstracts and cases.

SECTION 1: Submission Types

ACC.27-WCC is accepting submissions across the following four types:

1. **Abstracts:** The ACC aims to select the highest quality, original, novel, and contemporary research impacting cardiovascular care for presentation and discussion during ACC.27-WCC. Abstracts can be submitted in 63 different categories organized by pathway and special topic clinical area.
2. **Complex Clinical Cases:** The purpose of complex clinical case submissions is to identify and select challenging, original, and novel patient cases that highlight complicated decision making in clinical care for presentation. These cases should stimulate interprofessional discussion and collaborative problem solving during ACC.27-WCC and can be submitted in 12 different categories. Medical students, residents, fellows-in-training, medical doctors, and researchers are welcome to submit complex clinical cases.
3. **Cardiovascular Team (“CVT”) Abstracts:** The ACC aims to select the highest quality, original, novel, and contemporary research impacting cardiovascular care for presentation and discussion during ACC.27-WCC. CVT abstracts are open to allied health professionals, Advance Practice Registered Nurses (“APRNs”), Physician Associates/Physician Assistants (“PAs”), and Clinical Pharmacists/Advanced Practice Providers (“APPs”) and can be submitted in two different categories.
4. **Cardiovascular Team Cases:** The purpose of CVT case submissions is to identify and select challenging, original, and novel patient cases that highlight complicated decision making in clinical care for presentation. These cases should stimulate interprofessional discussion and collaborative



problem solving during ACC.27-WCC and can be submitted in 12 different categories. Allied health professionals, APRNs, PAs and APPs are welcome to submit.

SECTION 2: Submitting Your Abstract or Case

A: General Information

- The ACC.27-WCC Program Committee will determine the appropriate presentation format, based on the abstract/case topic and relationship to other abstracts/cases submitted. The ACC.27-WCC Program Committee reserves the right to establish other presentation formats and to assign accepted submissions to these formats.
- Accepted abstracts and cases will be scheduled as oral presentations, moderated poster presentations, or flatboard poster presentations. See below for a description of each type of presentation (page 8).
- All presentations and question and answer periods must be conducted in English.
- Accepted submissions will be published exactly as submitted in the April 2027 online version of the *Journal of the American College of Cardiology* ("JACC"). Full text of the abstracts and cases will be viewable in the online/mobile program planner systems beginning Monday, March 29, 2027, at 8 a.m. ET.
- Investigators/Authors do not need to be ACC members to submit an abstract/case or otherwise participate in ACC.27-WCC.
- ACC will not reimburse ACC.27-WCC abstract and case presenters for travel, hotel, or per diem expenses.
- Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association. If any such experimentation is undertaken, the presenting author must be able to provide copies of informed consents signed by human participants.
- The ACC.27-WCC Program Committee endorses the position of the American Association for the Advancement of Science ("AAAS") in requiring assurances of the responsible use of animals in scientific research. All submissions for consideration must be in compliance with these AAAS guidelines.
- We follow JACC guidance regarding the use of Artificial Intelligence (AI):
 - "Authors may use any tools, AI or otherwise, that help them write more clearly and effectively. But, they must fully own the words, the ideas, and the responsibility for what they submit. Disclosure that AI was used to assist writing is not necessary, and we expect that every author is deeply involved in every manuscript, stands behind every word, and is fully accountable for the submission."
 - For more information, see: [Tools, Not Ghosts: Artificial Intelligence, Writing, and Responsibility](#).

B: Submission Policies

- ACC.27-WCC abstracts and cases must be submitted by 1 p.m. ET on Tuesday, Oct. 6, 2026. The ACC is not responsible for the review of abstracts and cases that are not submitted by this deadline.



- Notifications will be emailed on Thursday, Jan. 7, 2027, regarding acceptance disposition to the person who is designed as the “presenting author” for each abstract/case.
- If your abstract/case is accepted, your notification will contain complete presentation information.
- Submissions with “INCOMPLETE” status cannot be processed.
- There is no limit to the number of abstracts/cases an author can submit. The submitting author is considered the presenting author, unless another co-author is appointed to present in the submission.
- Authors should submit their abstract and cases to only one submission type or category. An author must choose the category that best encompasses the submission subject within the activity. Be sure to review all the submission options before selecting and starting the submission process. Abstracts and cases will be checked for submission in all submission types; if duplication is found, only the latest submission will be forwarded for review.
- The Young Investigator Awards (“YIA”) submission system will be open until Friday, Aug. 14, 2026, at 1 p.m. ET. Submissions not accepted as YIA abstracts may be submitted by the author as regular abstracts during the abstract submission process. For additional information regarding the YIA submission process, visit the [YIA page](#).
- Authors must follow all instructions for completing the submission. Please see the Submission Instructions for more information.
- Clarity of expression will be considered in the review process. The overall quality of language used should ensure comprehension by the reader.
- Authors may use a maximum of five unique abbreviations in the body of the submission. Place abbreviations in parentheses after the full word the first time it appears. Abbreviations increase the difficulty of reading and evaluating abstracts/cases.
- Only commonly used abbreviations should appear in the title of the abstract/case.
- Proofread abstracts/cases carefully to avoid errors before they are submitted. The ACC is not authorized to make changes to a submission, including typographical errors. If an abstract/case is selected, it will be published exactly as submitted. Tables and graphics will appear in the exact manner submitted even if the submission quality is poor.
- Authors may return to the online submission system to edit abstracts/cases, revise information, correct typographical errors, tables, graphics, or delete a submission at any time before 1 p.m. ET on Tuesday, Oct. 6, 2026. After this time, the system will be closed and complete submissions will be forwarded for the review process. An author may not revise or resubmit an abstract/case to make changes or corrections after this deadline; instead, the submission may be withdrawn or, if accepted, the error may be indicated during the presentation.
- Adding or removing authors after the submission deadline is not permitted.
- **Only a submitting author and/or lead investigator may withdraw an abstract/case. If the submitting author and/or lead investigator chooses to withdraw an abstract/case after the submission deadline and does not want it to appear in ACC.27-WCC publications, written notification must be sent to atruluck@acc.org by Thursday, Feb. 4, 2027. After this date, withdrawals will be accepted and abstracts/cases will be withdrawn from the program. However, the text will still appear in JACC as submitted.**



- If you have submitted a late-breaking clinical trial with the same data as an accepted abstract and you do not withdraw your regular abstract by Thursday, Feb. 4, 2027, you will be in violation of the LBCT embargo.

C: Payment Policies

- There is a USD \$55 nonrefundable processing fee for each abstract/case submitted, payable online by credit card only. Purchase orders, checks, and electronic bank transfers will not be accepted.
- For CVT abstracts/cases, there is a USD \$25 nonrefundable processing fee for each submission, payable online by credit card only. Purchase orders, checks, and electronic bank transfers will not be accepted.
- This processing fee covers the cost of submission and processing of the abstract/case.
- **No processing fee refunds** will be given in the event of rejection or non-review of a duplicate submission.
- **No processing fee refunds** will be given in the event that an author requests to change the submission type (Abstract, Complex Clinical Case, CVT Abstract, or CVT Case) of their submission. If a submitter requires changing a submission type, the submitter will need to resubmit under the correct submission type and pay a new processing fee. No refund will be given for the original submission.

D: Registration For ACC.27-WCC

- Submission of an abstract/case constitutes a commitment by the author(s) to present at ACC.27-WCC if accepted. Failure to register for, and present at, ACC.27-WCC will jeopardize future acceptance of abstracts/cases submitted by the author.
- Presenters must register for ACC.27-WCC in the appropriate category (member, nonmember, etc.) and pay the applicable fees for the registration category. They will receive a discount for being an accepted abstract/case presenter.
- Registration opens October 2026. Check the ACC.27-WCC [registration page](#) for additional details.

E: Disclosure Policies

- The ACC.27-WCC Abstract and Case Program is a non-accredited activity. Therefore, presenting authors and lead investigators are not required to complete their disclosures prior to submitting an abstract/case.
- If an abstract/case is **accepted** to ACC.27-WCC, presenting authors must include both their and their lead investigator's disclosures on their poster or in their oral presentation.

F: Eligibility Policies

Please refer to the following table to determine eligibility for submission of abstracts/cases for presentation at ACC.27-WCC. These criteria protect the quality, originality, and integrity of the science and case discussions featured during ACC.27-WCC.



Eligible	Not Eligible
Abstracts/cases that have not previously been presented either live or virtually at another professional society meeting or published prior to ACC.27-WCC <i>are eligible</i> for submission.	Abstracts/cases are <i>not eligible</i> for consideration if they have been presented either live or virtually at a national meeting held in the United States or any non-ACC international meeting held prior to ACC.27-WCC.*
If an abstract/case has been presented (either live or virtually) only at an ACC state chapter meeting or ACC international meeting (ACC Asia, ACC Latin America, ACC Middle East), it <i>is eligible</i> for submission to ACC.27-WCC.	Abstracts/cases are <i>not eligible</i> for consideration if they have been presented live or virtually at programs held by non-profit organizations (e.g., ACC live U.S. courses).
If an abstract/case has been presented (either live or virtually) only to a state medical society or country society meeting, or local institutional meeting, it <i>is eligible</i> for submission to ACC.27-WCC.	Abstracts/cases are <i>not eligible</i> for consideration if the abstract has been published <i>prior</i> to ACC.27-WCC.
If an abstract/case is also planned for submission or presentation at a meeting taking place after ACC.27-WCC, it <i>is eligible</i> to be submitted to ACC.27-WCC.	If abstracts/cases are submitted to journals for publication and the journals <i>do not agree</i> to hold publication until the embargo is lifted and the abstract/case is published prior to that date, the abstract/case <i>must be withdrawn</i> from ACC.27-WCC.
Abstracts/cases may be submitted to journals for publication if the journals agree to <i>hold publication</i> until the ACC.27-WCC embargo is lifted on the designated day at 8 a.m. ET.	

* Examples of this type of meeting include, but are not limited to, scientific sessions by the American Heart Association, Heart Rhythm Society, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, and European Society of Cardiology.

Requests for exceptions to these eligibility requirements must be made in writing and will be reviewed by the ACC.27-WCC Program Committee leadership. These situations are expected to be rare given the comprehensive guidance as detailed above.

G: Publication and Copyright Policies

- For abstract/case submissions, the following applies:** On behalf of all co-authors, the submitting author/investigator agrees that the submission of an abstract/case constitutes the submitting author/investigator and all co-authors' agreement to assign and transfer to the ACC all rights, title, and interest, including copyright and all rights subsumed thereunder, in and to the abstract/case and



all material contained therein if the abstract/case is accepted. Except as otherwise set forth herein, the ACC, as holder of the copyright on the accepted abstract/case, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats. The assignment of copyright to ACC shall be required for, and the terms set forth in this section shall apply to, any and all abstracts/cases submitted or presented in any format, including but not limited to live, hard copy, or digital formats.

- **For accepted abstract/case presentations, the following applies:** On behalf of all co-authors, the submitting author/investigator agrees that the presentation of an abstract or case at or in connection with ACC.27-WCC constitutes the submitting author/investigator and all co-authors' agreement to assign and transfer to the ACC all rights, title, and interest, including copyright and all rights subsumed thereunder, in and to the abstract/case presentation and all material contained therein. Except as otherwise set forth herein, the ACC, as holder of the copyright on the abstract/case presentation, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats. The assignment of copyright to ACC shall be required for, and the terms set forth in this section shall apply to, any and all presentations in any format, including live, digital, or virtual formats.
- ACC hereby grants to the submitting author/investigator and the co-authors a non-exclusive, limited, nontransferable license to use the abstract/case and presentation and all content contained therein for educational, scientific, and research purposes, provided, however, that such license shall only be effective and such use is only permitted following the conclusion of ACC.27-WCC and after any embargoes in place on ACC.27-WCC content have been removed. Such license does not include the right for the authors/investigators, co-authors, or any sponsors to provide links to, or copies of, the abstract/case or presentations to third parties or ACC.27-WCC attendees in advance of or during ACC.27-WCC. Notwithstanding, the authors/investigators and co-authors are permitted to include a link to the abstract/case in their presentation.
- Subject to the prior approval of ACC and the payment of an applicable royalty fee, exhibitors may be granted a license to link to abstracts/cases or presentations from the exhibitor booth during ACC.27-WCC.
- On behalf of all co-authors, the submitting author/investigator agrees that any requests for reproduction, distribution, performance, display or the right to create derivative works of an abstract/case or presentation thereof shall be referred to ACC as the copyright holder.
- Primary responsibility for all data and content contained within an abstract/case and the presentation rests with the presenter, if the abstract/case is accepted/published. On behalf of all co-authors, the submitting author/investigator agrees that all data and content contained within an abstract/case and presentation shall be the original work of the authors/investigators and shall not violate or infringe the intellectual property rights of any third party.
- All abstracts/cases submitted in connection with ACC.27-WCC will be disclosed to members of the ACC.27-WCC peer review selection committee, as well as to ACC employees and contractors as necessary.
- ACC will undertake all reasonable efforts to maintain the confidentiality of abstracts/cases submitted but cannot guarantee the confidentiality of such materials.
- Titles, authors (and their institutions), and presentation time of accepted abstracts/cases will be posted in the online ACC.27-WCC Program Planner and the ACC.27-WCC App. Full text of accepted abstracts/cases will be published in the online ACC.27-WCC Program Planner and ACC.27-WCC App



beginning Monday, March 29, 2027 at 8 a.m. ET and the ACC.27-WCC online supplement of the *Journal of the American College of Cardiology* on Friday, April 9, 2027 at 8 a.m. ET.

- Abstracts/cases not accepted for presentation at ACC.27-WCC are not published by and will not be disclosed outside of ACC and persons associated with the selection process (e.g., the peer review selection committee). Proprietary rights in any abstracts/cases not selected for presentation at ACC.27-WCC, including copyright and all rights subsumed thereunder, shall remain with the submitting author/investigator and co-authors.
- Please read the [Media & Communication Policies](#) carefully as it contains information about Late-Breaking Clinical Trial Presentations. Researchers who believe they have legal obligations to disclose information in advance of presentation should contact the ACC Media Department for guidance. In the event that an author's/presenter's work will be published in a major peer reviewed medical journal concurrent with the timing of ACC.27-WCC, it is the responsibility of the abstract/case author/presenter to notify the ACC press office of the publication name and date as soon as possible to allow ACC to work with the publication to coordinate embargo of the material.

Section 3: Accepted Abstract/Case Policies

A: General Information

To the extent any live, virtual, or digital abstract/case presentation will include the participation of a patient or other individual, the abstract/case author(s) shall assume full responsibility for such presentation, including but not limited to any and all liability arising therefrom for any reason. It shall be the sole responsibility of the abstract/case author to obtain all necessary consents from the patient(s) or other individuals included in the submission or presentation, and to confirm to ACC that all necessary consents have been obtained prior to submission of the abstract/case for review by ACC.

The content in presentations shall be limited to medical, scientific, and research content which relates directly to the abstract/case submission. Presentations must not include any inappropriate or offensive content or any political or related messages. Presentations that do not conform to this requirement are subject to removal at the sole discretion of ACC.

B: Oral, Moderated, and Flatboard Poster Presentations

Oral Presentations

- All oral presentations will be programmed into ten (10)-minute time slots. Acceptance notifications will indicate the time and date of the presentation.
- All abstract presentations and question and answer periods will be conducted in English.
- Each oral abstract session in a pathway topic area will feature expert summary comments in a "year in review" talk.
- Timed presentations must adhere to the schedule. Presenters and session chairs share equal responsibility for maintaining the schedule of talks, as well as question and answer segments. Please be sure to stay within your allotted time to ensure that any Q&A/Panel Discussion segments may occur.
- One slide per minute is the recommended standard for presentations.



- A listing of the AV hardware/software provided for your session will be indicated in your acceptance notification. If you have any special AV requirements, such as proprietary software, etc., you will be able to confirm those requirements when you receive a link to upload your presentation. All special requirements are subject to review for approval at the sole discretion of ACC.

Moderated Poster Presentations

- All abstract/case moderated poster presentations will be programmed into ten (10)-minute time slots, including question and answer. Acceptance notifications will indicate the time and date of the presentation.
- All abstract/case presentations and question and answer periods will be conducted in English.
- Presenters create an electronic poster (ePoster) which will be displayed onsite via plasma monitors.
- Presenters must post disclosures for the presenting author and lead investigator on their ePoster. Failure to follow these guidelines may jeopardize the presentation at this and future ACC Scientific Sessions.
- There are two (2) moderators assigned per session.
- Sessions will occur in Moderated Theaters within the Poster Hall.
- Plain language summaries are not allowed in any part of the presentations, including links in a QR code, since they have not been peer reviewed.
- Acceptance notifications sent out in January 2027 will contain additional information about how to prepare ePoster presentations.

Flatboard Poster Presentations

- The majority of abstracts/cases accepted to ACC.27-WCC will be flatboard posters.
- Flatboard presenters must print their poster to mount on their designated board in the Poster Hall. Exact board size will be provided in acceptance notifications in January 2027.
- Presenters must post disclosures for the presenting author and lead investigator on their poster board. Failure to follow these guidelines may jeopardize the presentation at this and future ACC Scientific Sessions.
- Plain language summaries are not allowed in any part of the presentations, including links in a QR code, since the summaries have not been peer reviewed.
- The ACC is providing a poster printing service so presenters can order their posters directly through a vendor and pick up their poster in the Poster Hall in Houston.
- Acceptance notifications sent out in January 2027 will contain additional information about how to prepare flatboard poster presentations, poster templates, and the poster printing service.

C: ePoster Policies

The ACC.27-WCC Program Committee is committed to the use of an online poster (ePoster) system for self-study and archival purposes, which offers benefits to authors/investigators, and users, both during and after ACC.27-WCC. The ACC's ePoster system provides:

- Access based on applicable registration categories at ACC.27-WCC.
- Increased exposure of research, including social media capabilities.
- Robust search and browse functionality within the ePoster Viewer.



All flatboard and moderated poster presenters will be required to upload their presentation to the ePoster system. The specific requirements will be outlined in acceptance letters.

Additional information and instructions will be sent to presenters in January 2027.